You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國產首家!四環醫藥(00460.HK)新型抗血栓形成藥替格瑞洛分散片獲批上市
格隆匯 06-26 12:04

格隆匯6月26日丨四環醫藥(00460.HK)宣佈,集團附屬公司弘和製藥有限公司("弘和製藥")研發的替格瑞洛分散片(規格:90mg)("該產品")獲得中國國家藥監局頒發的藥品註冊批件,可視同通過仿製藥質量和療效一致性評價。弘和製藥研發的該產品為國產首家獲批上市。

替格瑞洛是一種新型抗血栓形成藥,具有強效抗血小板聚預防血栓形成的作用。目前已被國內外指南推薦為心血管疾病患者進行血栓預防的抗血小板藥物。替格瑞洛分散片屬於國家醫保乙類產品。

根據公開數據,法伯核心醫院市場數據顯示,2023年我國核心醫院口服類抗凝藥市場規模超過人民幣100億元。心腦血管領域為本集團重點佈局領域,本次替格瑞洛分散片獲批上市,將進一步惠及廣大患者,同時為集團的心腦血管領域藥物管線再添一重要品種,對集團的經營業績產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account